AMES, Iowa, May 06, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that the company will participate in the following investor and medical conferences:
Bank of America Merrill Lynch Global Health Care Conference 2019 on May 14-16 in Las Vegas
- Management will present on Thursday, May 16 at 8:40 AM PT / 11:40 AM ET
Immuno-Oncology 2019 World Congress on May 23-24 in Barcelona, Spain
- Poster presentation of Abstract #188 entitled, “A Phase 1 Clinical Trial of NLG802, a Prodrug of Indoximod with Enhanced Pharmacokinetic Properties”
A live webcast of the Bank of America Merrill Lynch Health Care Conference presentation will be available on the Company’s website at www.newlinkgenetics.com in the “Investors & Media” section under “Events and Presentations.”
The poster to be presented at the Immuno-Oncology 2019 World Congress will be available on the Company’s website www.newlinkgenetics.com at 8:30 AM ET in the “Investors & Media” section under “Posters & Publications.”
About NewLink Genetics Corporation
NewLink Genetics is a clinical stage biopharmaceutical company focusing on developing novel oncology product candidates to improve the lives of patients with cancer. NewLink Genetics' IDO pathway inhibitors, indoximod and its prodrug, NLG802, are immuno-oncology drug candidates designed to harness multiple components of the immune system to combat cancer. NewLink Genetics’ drug candidate, NLG207 (formerly CRLX101), a nanoparticle formulation of topoisomerase 1 inhibitor, camptothecin, is under development to combat refractory malignancies. For more information, please visit www.NewLinkGenetics.com and follow us on Twitter @NLNKGenetics.
Investor & Media Contact:
Lisa Miller
Director of Investor Relations
NewLink Genetics
515-598-2555
lmiller@linkp.com
Source: NewLink Genetics Corporation
Source: NewLink Genetics Corporation
